Last updated Nov 3, 2026
A male infant has prolonged bleeding after circumcision. He later develops hemarthroses with minor trauma. PTT is prolonged, PT is normal. Factor VIII is <1%.
XLR; F8, encoding coagulation factor VIII. Loss-of-function variants; inversions involving intron 22 or intron 1 account for about half of severe disease.
Severity:
- Severe (<1%): Spontaneous bleeding, hemarthroses
- Moderate (1-5%): Bleeding with minor trauma
- Mild (5-40%): Bleeding with surgery/trauma
Factor VIII is made mainly in liver sinusoidal endothelial cells and circulates as an inactive cofactor, stabilized by binding to von Willebrand factor. Trace thrombin activates it and releases it; it then binds phospholipid surfaces such as activated platelets and, with factor IXa, becomes the "intrinsic system" activator of factor X, an early step in coagulation.
Pathogenic variants cause loss of function. Most people with severe disease have no detectable factor VIII protein; others have normal amounts of a dysfunctional protein, or reduced levels because the protein is poorly secreted or unstable in circulation. Variant class predicts severity. Intron 22 inversions (about 45% of severe disease, from recombination with homologous copies 400-500 kb away), intron 1 inversions, nonsense variants, and most frameshifts cause severe disease, while missense variants are found in nearly all mild and moderate disease.
Variant class also predicts alloimmune inhibitors to infused factor VIII. Certain premature stop codons, inversions, and large gene alterations carry an especially high risk; in mild or moderate disease, missense variants such as p.Arg612Cys and p.Arg2169His raise it.
- Hemarthroses (ankles, knees, elbows)
- Muscle hematomas
- Prolonged PTT, normal PT
- Carrier females may have mild symptoms
- Prolonged aPTT with normal PT; a mixing study corrects, indicating factor deficiency rather than an inhibitor
- Reduced factor VIII activity assay confirms and grades severity (severe <1%, moderate 1-5%, mild 5-40%); normal von Willebrand factor distinguishes from von Willebrand disease
- F8 molecular testing (intron 22 inversion first, then sequencing/del-dup) confirms the diagnosis, enables carrier testing of at-risk females, and supports prenatal diagnosis
- Factor VIII replacement, emicizumab (bispecific antibody), gene therapy
ADH for Hemophilia A: Treatment includes ADH (desmopressin/DDAVP) for mild hemophilia A. Inheritance is XLR, so it primarily affects boys (same as Hemophilia B).
Hemophilia = "He" disease: Like Hemochromatosis, Hunter syndrome (MPS II), and Hirschsprung disease, hemophilia is male-predominant.
Approximately 50% of severe hemophilia A cases are caused by inversions in the F8 gene at Xq28. The intron 22 inversion accounts for about 43%-45% and intron 1 inversion for 2%-5% of severe cases.
